Comments
Transgene Biotek has said it will start commercial production of active pharmaceutical ingredient DHA, which is used for reducing heart diseases and strengthening the nervous system.
“We have completed the production of this product in pilot batches and now plan to commence commercial production shortly at a third party facility having large fermentation infrastructure,” Transgene Biotek said in a filing to the Bombay Stock Exchange today.
The company claimed that according to a Frost & Sullivan report, the market for Omega-3 fatty acids is expected to grow over 62 per cent in the coming years. The market for Omega-3 fatty acids was estimated at $2 billion in 2007.
Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EHA) are Omega-3 fatty acids and are used as a supplement in foods, food ingredients, beverages, nutritional oils and consumer health products, besides the pharmaceutical industry.
Meanwhile, the shares of Transgene Biotek were trading at Rs 44.25 apiece on the BSE in the afternoon today, up 4.98 per cent from the previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.